These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24929963)

  • 61. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prospective evaluation of qualitative and quantitative ¹⁸F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix.
    Maharjan S; Sharma P; Patel CD; Sharma DN; Dhull VS; Jain SK; Thulkar S; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Aug; 34(8):741-8. PubMed ID: 23676840
    [TBL] [Abstract][Full Text] [Related]  

  • 63. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.
    Spence AM; Muzi M; Link JM; O'Sullivan F; Eary JF; Hoffman JM; Shankar LK; Krohn KA
    Mol Imaging Biol; 2009; 11(5):343-55. PubMed ID: 19326172
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI,
    Collet S; Guillamo JS; Berro DH; Chakhoyan A; Constans JM; Lechapt-Zalcman E; Derlon JM; Hatt M; Visvikis D; Guillouet S; Perrio C; Bernaudin M; Valable S
    J Nucl Med; 2021 Oct; 62(10):1349-1356. PubMed ID: 34016725
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET.
    Morana G; Piccardo A; Tortora D; Puntoni M; Severino M; Nozza P; Ravegnani M; Consales A; Mascelli S; Raso A; Cabria M; Verrico A; Milanaccio C; Rossi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2084-2093. PubMed ID: 28752225
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The roles of
    Kim S; Kim D; Kim SH; Park MA; Chang JH; Yun M
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):1012-1020. PubMed ID: 29511838
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations.
    Saga T; Kawashima H; Araki N; Takahashi JA; Nakashima Y; Higashi T; Oya N; Mukai T; Hojo M; Hashimoto N; Manabe T; Hiraoka M; Togashi K
    Clin Nucl Med; 2006 Dec; 31(12):774-80. PubMed ID: 17117071
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
    Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM
    J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differentiating high-grade glioma progression from treatment-related changes with dynamic [
    Rozenblum L; Zaragori T; Tran S; Morales-Martinez A; Taillandier L; Blonski M; Rech F; Galanaud D; Kas A; Verger A
    Eur Radiol; 2023 Apr; 33(4):2548-2560. PubMed ID: 36367578
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic value of
    Moller S; Law I; Munck Af Rosenschold P; Costa J; Poulsen HS; Engelholm SA; Engelholm S
    Radiother Oncol; 2016 Oct; 121(1):132-137. PubMed ID: 27622554
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.
    Youland RS; Pafundi DH; Brinkmann DH; Lowe VJ; Morris JM; Kemp BJ; Hunt CH; Giannini C; Parney IF; Laack NN
    J Neurooncol; 2018 May; 137(3):583-591. PubMed ID: 29330751
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.
    Colavolpe C; Metellus P; Mancini J; Barrie M; Béquet-Boucard C; Figarella-Branger D; Mundler O; Chinot O; Guedj E
    J Neurooncol; 2012 May; 107(3):527-35. PubMed ID: 22169956
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
    Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
    Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 78. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.
    Barker FG; Chang SM; Valk PE; Pounds TR; Prados MD
    Cancer; 1997 Jan; 79(1):115-26. PubMed ID: 8988735
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Assessment of grading in newly-diagnosed glioma using 18F-fluorothymidine PET/CT.
    Ferdová E; Ferda J; Baxa J; Tupý R; Mraček J; Topolčan O; Hes O
    Anticancer Res; 2015 Feb; 35(2):955-9. PubMed ID: 25667480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.